15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 12 firms covering Trevi Therapeutics Inc, 12 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $16.00 to $36.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $24.08 sits 43% above the current $16.81. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 11 to 12 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.14 next quarter toward $-0.58 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 ratings
Strong Buy
Strong Buy00%
Buy12100%
Hold00%
Sell00%
Strong Sell00%
Based on 12 analysts giving stock ratings to Trevi Therapeutics Inc.
As of Sep, 12 of 12 firms rate TRVI a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
TRVI EPS & revenue forecast
EPS · NEXT QUARTER
$-0.14
Range $-0.20 – $-0.07 · 10 analysts · +138% YoY
Next period, 10 analysts expect Trevi Therapeutics Inc to earn $-0.14 a share (range $-0.20 – $-0.07), versus $-0.06 a year earlier. Full-year consensus is $-0.48, growing to $-0.58 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 10 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Trevi Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TRVI.
#1
Mayank Mamtani
B. Riley Securities · Rank #41
Buy
$31.00+84.4% to target
Overall win rate
50%
+ Follow
#2
Serge Belanger
Needham · Rank #105
Buy
$23.00+36.8% to target
Overall win rate
48%
+ Follow
#3
Josh Schimmer
Cantor Fitzgerald · Rank #162
Buy
$30.00+78.5% to target
Overall win rate
38%
+ Follow
#4
Oren Livnat
HC Wainwright & Co. · Rank #170
Buy
$12.50-25.6% to target
Overall win rate
54%
+ Follow
#5
BF
Brandon Folkes
HC Wainwright & Co. · Rank #221
Buy
$24.00+42.8% to target
Overall win rate
42%
+ Follow
TRVI stock forecast FAQ
What is TRVI's average 12-month price target?+
The 12 analysts with a live target average $24.08 for Trevi Therapeutics Inc over the next 12 months, ranging from a $36.00 high to a $16.00 low.
Is TRVI stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 12 analyst ratings, 12 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for TRVI?+
The Street-high target is $36.00 (BMO Capital), and the Street-low is $16.00 (Leerink Partners). The average of all 12 active targets is $24.08.
How many Wall Street analysts cover TRVI?+
12 analysts have an active rating on Trevi Therapeutics Inc, and 12 firms carry a live 12-month price target.
Who is the most accurate analyst covering TRVI?+
Among analysts who currently cover TRVI, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #41). Their current call is Buy with a $31.00 target.
What is Trevi Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.14 per share (range $-0.20 – $-0.07) across 10 analysts. Full-year EPS is projected at $-0.48, rising to $-0.58 the following year.
How much revenue is Trevi Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading TRVI lately?+
As of Sep, 12 of 12 firms rate TRVI a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TRVI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
BMO Capital
